Purpose The introduction of ligands targeting prostate-specific membrane antigen (PSMA), especially 68 Ga-PSMA-11, has changed the management of patients with prostate cancer (PCa).
Introduction
Prostate cancer (PCa) is the most frequent tumour disease in men worldwide [1] . Biochemical relapse is frequent after initial curative treatment, especially in patients with high-risk PCa. Conventional imaging with, for example, computed tomography (CT) and magnetic resonance imaging (MRI), are insufficient in detecting tumour lesions due to their low sensitivity and specificity. During recent years targeted imaging of prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, N-acetyl-α-linked acidic dipeptidase I or folate hydrolase, has opened a new chapter in the diagnostic management of patients with PCa [2] [3] [4] [5] [6] . PSMA is a type II transmembrane glycoprotein that is strongly overexpressed in PCa cells. The level of PSMA expression rises with increasing tumour dedifferentiation and is higher in hormone-refractory cancers [7] [8] [9] .
Because of the larger activity amount of cyclotronproduced 18 F compared with the limited activity of 68 Ga derived from 68 Ge/ 68 Ga generator elution, and its longer half-life and higher physical spatial resolution, 18 F has advantages over 68 Ga [10] . Furthermore, the very low urinary activity in 18 F-PSMA-1007 PET/CT scans seems to be another advantage, which makes this new imaging pharmaceutical highly interesting for the differentiation of lymph node metastases of recurrent PCa from urinary activity in the ureter or for the differentiation of local relapse from the urinary bladder [11] .
The first clinical experience in single cases or case series with 18 F-PSMA-1007 has shown the potential of this new radiopharmaceutical in patients with PCa [11] [12] [13] [14] . The aim of the present study was to evaluate the performance of 18 F-PSMA-1007 in detecting PCa recurrence or metastases in patients with biochemical relapse.
Materials and methods

Patients
From October 2017 to May 2018, 212 patients were examined with 18 F-PSMA-1007 PET/CT as part of clinical routine. Of these patients, 100 were referred for the detection of recurrent PCa. The patients received primary therapy for PCa a median of 44.3 months before PSMA imaging (range 2-314 months). In seven patients, the exact time of the first therapy for PCa was not available. Some of the patients had undergone CT, MRI or bone scan before PSMA imaging. However, a systematic comparison of these data was not possible since the intervals were highly variable and different procedures had been performed. All other imaging studies performed before PET/ CT had been negative. Of the 100 patients, 28 had been analysed previously in a dual time scanning analysis [14] .
Patient characteristics are given in Table 1 . Patients with no primary therapy with curative intent or patients referred for PSMA radioligand therapy were not included in the current analysis (Fig. 1) . Prostatectomy, radiation beam therapy and androgen-deprivation therapy had been performed in 92%, 45% and 27% of the patients. Radiation beam therapy in addition to surgery had been performed in 38 patients (38%) and 10 patients (10%) had received all three therapy modalities. All patients received detailed information about the imaging procedures and provided signed informed consent according institutional guidelines.
Imaging procedures and preparation of 18 F-PSMA-1007 18 F-PSMA-1007 was produced in a GE TracerLab MX synthesizer according to the one-step procedure described by Cardinale et al. and standard operation procedures described previously [14, 15] including sterile filtration of the final batch solution. 18 F-PSMA-1007 precursor, cassettes and reagents for the synthesis of 18 F-PSMA-1007 as well as the synthesis sequence for fully automatic production with a GE TracerLab MX module were obtained from ABX GmbH (Radeberg, Germany). The final injection solution of the 18 F-PSMA-1007 batch was clear, colourless and particle-free, and had a mean radiochemical purity of 96.5 ± 1.1% (range 95-99%) as determined by high-performance liquid chromatography. Unreacted 18 F-fluoride or 18 F-fluoride resulting from compound cleavage was not detected by thin-layer chromatography. The pH of the batch solution ranged from 5.9 to 7.8 and the endotoxin content was <5.0 endotoxin units/ml. The concentrations of ethanol and dimethyl sulfoxide (DMSO) as residual solvents were measured by gas chromatography (ethanol 29.6-31.6 mg/ml; DMSO 0.25-0.68 mg/ml). The osmolality ranged from 1,110 to 1,300 mOsmol/kg.
Patients received 4 MBq/kg body weight with a maximum of 400 MBq per patient (mean injected activity 338 ± 44.31 MBq). Scanning was performed 120 min after injection from the lower limbs to the skull. Patients were asked to empty their bladder before the scan. Images were acquired with a scan time of 3 min per bed position on a Siemens mCT scanner (Siemens Healthcare, Knoxville, TN). Images were 
Image analysis
Coregistered images were analysed using syngovia software, version: VB20A (Siemens Healthcare). According to institutional procedures all scans were analysed by two boardcertified nuclear medicine physicians and radiologists at an interdisciplinary conference for reporting. Absence of morphological changes was regularly found and were classified as bone metastases and local recurrence. The sensitivity of CT for these types of metastases is known to be limited, and thus high focal tracer uptake in these areas was considered suggestive of bone metastases or local recurrence despite a lack of morphological correlation. In lesions characteristic of PCa, volumes of interest were placed on the plane with highest uptake, and maximum standardized uptake values (SUV max ) were measured and documented. Focal tracer uptake above local background in morphologically visible lesions on CT was considered as PSMA-positive. Any visible PCa lesions were analysed unless the patients had more than three lesions, in which case, a maximum of three lesions were analysed. This kind of selection avoids overestimation of SUVs as otherwise dominant lesions would be preferentially selected. Typical pitfalls such as PSMA uptake in sacral and coeliac ganglia or in the stellate ganglia were frequently observed but were not considered pathological [16] .
Statistical analysis
SPSS Statistics 25 (IBM Inc. Armonk, NY, USA) was used for statistical analysis. Descriptive statistics are absolute and relative frequencies, mean or median and standard deviation or range, were used to characterize the study population. For subgroup analysis, patients were divided into four groups depending on their prostate-specific antigen (PSA) level: ≤0.5, 0.51-1.0, 1.1-2.0 and >2.0 ng/ml. The Mann-Whitney test was used to evaluate the significant differences of the median SUV max (of the lesion with maximum uptake from each patient) between PSA groups. A P value <0.05 was considered significant and noticeable.
Results
The analysis included 100 consecutive patients (mean age 68.75 ± 7.6 years) who were referred for 18 F-PSMA-1007 PET/CT for evaluation and localization of biochemical relapse. None of the patients showed any kind of adverse event or clinically detectable pharmacological effect following injection of 18 F-PSMA-1007. In 95 of the 100 patients (95%) at least one lesion suggestive of PCa was detected on 18 F-PSMA-1007 PET/CT. The patient-based sensitivity was therefore 95% (95% confidence interval 91-99%). In total, 213 lesions characteristic of PCa (37 local relapses, 107 lymph node metastases, 67 bone metastases and 2 soft tissue metastases) were detected in 95 patients, and in 29 patients relapse was exclusively lymph node metastases, in 16 patients exclusively bone metastases and in 15 patients exclusively local relapse. Table 2 presents the average SUV max of all included lesions. Examples of a bone lesion, a lymph node and a local relapse are given in Figs. 2, 3 and 4 .
Of patients with a PSA level ≤2.0 ng/ml, 92% were PETpositive. The rates of pathological 18 F-PSMA-1007 PET/CT scans in relation to PSA level and Gleason score (GS) are presented in Fig. 5 . In total, 18 F-PSMA-1007 PET/CT was negative in five patients, three with a PSA level ≤0.5 ng/ml and two with a PSA level in the range 0.51-1.0 ng/ml. 212 patients referred for 18 F-PSMA-1007 PET/CT Study population n = 100 referred for evaluation and localization of biochemical relapse n = 112 patients excluded (already known PSMA metastases, patients referred to PSMA tergeted radioligand therapy or patients without curative intended therapy) Fig. 1 Flow chart of patient selection
The majority of patients (70) with a GS available had a score in the range 7-9. The detection rate in these patients was 93% (65/70). The median SUV max values of the pathological findings in patients with PSA levels ≤0.5, 0.51-1.0, 1.1-2.0 and > 2.0 ng/ml were 10.25 (range 3.98-48.99), 14.32 (range 4.36-38.61), 13.16 (range 3.14-136.18) and 28.87 (range 5.03-248.27), respectively. The median SUV max in patients with a PSA level >2.0 ng/ml was significantly higher than that in patients in the other PSA groups (>2.0 ng/ml vs. ≤0.5 ng/ml, P = 0.001; vs. 0.51-1.0 ng/ml, P = 0.005; vs. 1.1-2.0 ng/ml, P = 0.027). There were no significant differences among the other PSA groups.
Discussion
PSMA-targeted imaging has achieved a leading role in the management of PCa patients during recent years overcoming the challenging lack of sensitivity and specificity of conventional imaging modalities. In the present study the performance of 18 F-PSMA-1007 in detecting PCa lesions in patients with biochemical relapse was evaluated.
18 F-PSMA-1007 PET/CT scans in 100 consecutive patients referred for evaluation and localization of biochemical relapse were retrospectively analysed. Of all the patients included in this analysis, 95% showed at least one lesion with characteristics suggestive [17] , which is lower than in the present study, but the detection rate found in that study might have been due to the small number of patients. In the study mentioned, 62% of the patients who had a PSA level ≤2.0 ng/ml had a pathological scan, whereas in our study 92% of the patients (56/61) with a PSA level of ≤2.0 ng/ml had a pathologic scan.
The PET-positive rate in the present study was higher than the detection rate in a study investigating the performance of 68 Ga-PSMA-11 PET/CT in 1007 patients with biochemical relapse (the largest group investigated so far) [3] . In that study the detection rate was 79.5% in patients with a median PSA level of 2.2 ng/ml compared with 95% in the present study and a median PSA level of 1.34 ng/ml. In another study also using 68 Ga-PSMA-11, the detection rate was 89.5% in 248 patients with biochemical relapse and a median PSA level of 1.99 ng/ml [18] . In that study, the detection rate in patients with a PSA level <0.5 ng/ml was 57.9% (11/19) compared with a rate of 86% (18/21) in our study. Although the patient groups are not directly comparable (e.g. different proportions of patients with previous surgical treatment), our results could indicate that 18 F-PSMA-1007 has a higher sensitivity than 68 Ga-PSMA-11. However, further studies including more patients are mandatory to further analyse the sensitivity of 18 F-PSMA-1007.
In the present study, local relapse was detected in 37% of patients (37/100), which is considerably higher than found in a recent study using 68 Ga-PSMA-11 in which local relapse was detected in 4% of patients (13/319) [2] . Our results suggest that 18 F-PSMA-1007 might be superior to 68 Ga-PSMA-11, especially in patients with a low PSA level. However, this suggestion must be further evaluated in a head to head comparison, which is not yet available. Furthermore, it is well known from 68 Ga-PSMA-11 and 18 F-PSMA-1007 studies that PCa lesions are shown with better contrast and higher tracer uptake after longer uptake times (e.g. 3 h rather than 1 h after injection) [2, 6, 14] . This indicates that imaging with 18 F-PSMA-1007 is probably more advantageous at 2 h than at 1 h after injection, which has become common with 68 Ga-PSMA-11 at most centres. The longer half-life and higher injected activities allow high-quality delayed images, higher lesion uptake and superior clearance of background activity. The higher detection rate may therefore be because of the superior differentiation of ureter and bladder activity from local recurrence and locoregional lymph node metastasis [11, 14] . The confidence in diagnosing local recurrence is thus enhanced. Particularly in patients with a low PSA level, radiotherapy of local recurrences may induce secondary complete remission. A reliable imaging procedure for use in patients with increasing but still low PSA levels is thus of the utmost clinical relevance. The nonsignificant differences in median SUV max among the subgroups of patients with a PSA level ≤2.0 ng/ml underlines the high detection rates revealed in the present analysis in patients with a very low PSA level (e.g. ≤0.5 ng/ml). A lower PSA threshold level can thus not be recommended since tumour lesions can be visualized with high sensitivity due to high uptake.
High liver and bowel uptake of 18 F-PSMA-1007 has been reported. This was also found in the present group of patients. Since isolated liver metastases occur infrequently and bowel metastases very rarely, we consider that the high uptake in these organs would not cause a marked deterioration in the sensitivity of the tracer. In the present study, the sensitivity of 18 F-PSMA-1007 PET/CT seemed to be independent of the GS. Prior studies using 68 Ga-PSMA-11 have only shown a probable tendency for higher detection rates with increasing GS [3] .
The lack of histopathology was a limitation of the present study. Therefore, we cannot exclude false-positive lesions, although the images were analysed by physicians with long experience of PET imaging, especially PCa imaging with PSMA-targeted radioligands.
Conclusion
18
F-PSMA-1007 PET/CT can detect recurrent PCa in a high percentage of patients with biochemical relapse. The probability of a pathological 18 F-PSMA-1007 PET/CT seems to be high even in patients with a low PSA level of ≤0.5 ng/ml, which may have a significant impact in the further clinical management of patients. Prospective controlled trials are mandatory to validate these data.
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